<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00658554</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 197-113</org_study_id>
    <nct_id>NCT00658554</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers</brief_title>
  <official_title>Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck &amp; Co., Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck &amp; Co., Inc.)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a bioequivalence study designed to compare three solid states of ARQ 197 in normal&#xD;
      healthy volunteers using a randomized crossover design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a bioequivalence study designed to compare three solid states of ARQ 197 in normal&#xD;
      healthy volunteers using a randomized crossover design.&#xD;
&#xD;
      The primary objective is to obtain pharmacokinetic data to assess bioequivalence among three&#xD;
      solid states of ARQ 197: amorphous, crystalline polymorph A and crystalline polymorph B.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To obtain pharmacokinetic data to assess bioequivalence among three solid states of ARQ 197: amorphous, crystalline polymorph A and crystalline polymorph B.</measure>
    <time_frame>May 2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To monitor safety of the three solid states of ARQ 197.</measure>
    <time_frame>May 2008</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ 197</intervention_name>
    <description>Treatment with ARQ 197</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must provide written informed consent prior to any study related procedures&#xD;
&#xD;
          -  Subjects must be between the ages of 18 and 65 years&#xD;
&#xD;
          -  Male participants must have been surgically sterilized&#xD;
&#xD;
          -  Female participants must have been surgically sterilized or be post menopausal and&#xD;
             must have a negative serum pregnancy test&#xD;
&#xD;
          -  All participants will be phenotypically extensive metabolizers based on their CYP C19&#xD;
             genotype.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Males who are not surgically sterilized&#xD;
&#xD;
          -  Females of child-bearing potential who are not surgically sterilized&#xD;
&#xD;
          -  Any clinically significant acute or unstable physical or psychological disease based&#xD;
             on medical history or screening physical examination&#xD;
&#xD;
          -  Any clinically significant abnormality in the screening laboratory tests or ECG&#xD;
&#xD;
          -  Received any investigational drugs within four weeks&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)&#xD;
             infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M Kimberlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>April 11, 2008</study_first_submitted>
  <study_first_submitted_qc>April 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2008</study_first_posted>
  <last_update_submitted>June 18, 2008</last_update_submitted>
  <last_update_submitted_qc>June 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Nigel Rulewski, MD Chief Medical Officer</name_title>
    <organization>ArQule</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

